The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
复制标题
DOI：
10.1016/j.cell.2021.12.032
复制
发表时间：
2022-02-03
期刊：
影响因子：
64.5
通讯作者：
Pöhlmann S
中科院分区：
文献类型：
--
作者：
Hoffmann M;Krüger N;Schulz S;Cossmann A;Rocha C;Kempf A;Nehlmeier I;Graichen L;Moldenhauer AS;Winkler MS;Lier M;Dopfer-Jablonka A;Jäck HM;Behrens GMN;Pöhlmann S
SARS-CoV-2 Omicron变种的快速传播表明，该病毒可能在全球范围内占据主导地位。此外，病毒刺突蛋白的大量突变引起了人们的担忧，即病毒可能会逃避感染或疫苗接种引起的抗体。在这里，我们报告了奥米克龙尖峰对大多数治疗性抗体具有抵抗力，但仍然对Sotrovimab的抑制敏感。同样，Omicron峰值避免了恢复期患者或接种了BioNTech-Pfizer疫苗(BNT162b2)的个人的抗体的中和，其效率比Delta变体的峰值高12至44倍。用异源ChAdOx1(Astra Zeneca-Oxford)/BNT162b2疫苗或三种剂量的BNT162b2疫苗诱导的抗体中和Omicron穗的效果更好，但Omicron穗仍然比Delta穗更有效地逃避中和。这些发现表明，大多数治疗性抗体对Omicron变种无效，BNT162b2双重免疫可能不足以预防该变种引起的严重疾病。SARS-CoV-2 Omicron变种正在全球迅速传播，并成为一个公共卫生问题。实验表明，该变异体能抵抗多种新冠肺炎治疗性抗体，并能有效地避开感染或二次接种BNT162b2疫苗时产生的抗体，而不是三次BNT162b2或ChAdOx1/BNT162b2疫苗接种时产生的抗体。
The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by sotrovimab. Similarly, the Omicron spike evaded neutralization by antibodies from convalescent patients or individuals vaccinated with the BioNTech-Pfizer vaccine (BNT162b2) with 12- to 44-fold higher efficiency than the spike of the Delta variant. Neutralization of the Omicron spike by antibodies induced upon heterologous ChAdOx1 (Astra Zeneca-Oxford)/BNT162b2 vaccination or vaccination with three doses of BNT162b2 was more efficient, but the Omicron spike still evaded neutralization more efficiently than the Delta spike. These findings indicate that most therapeutic antibodies will be ineffective against the Omicron variant and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant. The SARS-CoV-2 Omicron variant is rapidly spreading worldwide and a public health concern. Experiments show that this variant is resistant against several therapeutic antibodies for COVID-19 and efficiently evades antibodies induced upon infection or double BNT162b2 vaccination, but not triple BNT162b2 or ChAdOx1/BNT162b2 vaccination.
登录
查看更多内容
DOI：
10.1056/nejmoa2102685
发表时间：
2021-10-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Dougan M;Nirula A;Azizad M;Mocherla B;Gottlieb RL;Chen P;Hebert C;Perry R;Boscia J;Heller B;Morris J;Crystal C;Igbinadolor A;Huhn G;Cardona J;Shawa I;Kumar P;Adams AC;Van Naarden J;Custer KL;Durante M;Oakley G;Schade AE;Holzer TR;Ebert PJ;Higgs RE;Kallewaard NL;Sabo J;Patel DR;Dabora MC;Klekotka P;Shen L;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
DOI：
10.1056/nejmoa2115926
发表时间：
2021-12-23
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bar-On YM;Goldberg Y;Mandel M;Bodenheimer O;Freedman L;Alroy-Preis S;Ash N;Huppert A;Milo R
通讯作者：
Milo R
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
56.9
作者：
Cai, Yongfei;Zhang, Jun;Chen, Bing
通讯作者：
Chen, Bing
影响因子：
17.1
作者：
Jones BE;Brown-Augsburger PL;Corbett KS;Westendorf K;Davies J;Cujec TP;Wiethoff CM;Blackbourne JL;Heinz BA;Foster D;Higgs RE;Balasubramaniam D;Wang L;Zhang Y;Yang ES;Bidshahri R;Kraft L;Hwang Y;Žentelis S;Jepson KR;Goya R;Smith MA;Collins DW;Hinshaw SJ;Tycho SA;Pellacani D;Xiang P;Muthuraman K;Sobhanifar S;Piper MH;Triana FJ;Hendle J;Pustilnik A;Adams AC;Berens SJ;Baric RS;Martinez DR;Cross RW;Geisbert TW;Borisevich V;Abiona O;Belli HM;de Vries M;Mohamed A;Dittmann M;Samanovic MI;Mulligan MJ;Goldsmith JA;Hsieh CL;Johnson NV;Wrapp D;McLellan JS;Barnhart BC;Graham BS;Mascola JR;Hansen CL;Falconer E
通讯作者：
Falconer E